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Different vimentin expression in two clones derived from a human
colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin
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M Broggini'
'Istituto di Ricerche Farmacologiche 'Mario Negri', via Eritrea 62, 20157 Milan, Italy; 2Istituto di Anatomia Patologica
Veterinaria e Patologia Aviare and 3Dipartimento di Biologia e Genetica, University ofMilan, Italy.
Sm_mary We seketed two clones, isolated from the human colocainoma cell line LoVo, showing a
sensitivity to doxorubicin similar to (LoVo clone 5) or three times lower than (LoVo clone 7) the parental cell
line. Since vimentin was atypically expressed in a human breast carcinoma cell line made resistant to
doxorubicin, we looked at vimentin expression in these two clones with spontaneously different sensitivity to
the drug. For comparison we used the parental cell line LoVo WT and LoVolDX made resistant phar-
macologically. mRNA for vimentin was undetectable by Northern blot analysis in LoVo WT and in LoVo
clone 5, while expression of this gene was high in LoVo clone 7 and in LoVo,lDX. This increase in mRNA
levels was not related to an amplification of DNA, as suggested by Southern blot analysis. Immuno-
fluorescence and immunocytochemistry findings confirmed, at protein level, the mRNA data. In LoVo clones 5
and 7, there were respectively 8.6% and 71% vimentin-positive cells, although the two clones showed similar
expression of multidrug resistance gene 1 (mdr-1) and accumulated intracellular doxorubicin at similar levels.
Similarly, drug efflux was the same for both clones. Our results show for the first time that cells resistant to
doxorubicin express vimentin independently of the mdr glycoprotein. However when cells from clone 5 were
transfected with human vimentin cDNA, they did not become resistant, indicating that vimentin can be
considered as a marker of resistance in these cells but does not give rnse to a resistant phenotype by
itself.
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Vimentin is an intermediate filament protein expressed by all
mesenchymal tissues (Steinert and Roop, 1988). Its function
is still unclear, although it changes its structure during cell
division from a cytoskeletal network during interphase,
becoming hyperphosphorylated when entering mitosis (Evans
and Fink, 1982; Chou et al., 1989). This is followed by a
complete reorganisation of the protein system (Aubin et al.,
1980; Franke et al., 1984).
Intermediate filaments, particularly vimentin, have been
suggested to be DNA-binding proteins, and the sequence
recognised by vimentin on DNA is homologous to the
steroid hormone receptor sequence. Normally epithelial cells
express keratins and not vimentin (Steinert and Roop, 1988).
This protein is expressed during neoplastic transformation
and in some cases during cell culture, and in fact acquisition
of vimentin expression has been shown in human breast
carcinoma cell lines (Sommers et al., 1989; Thompson et al.,
1992), in coexpression with keratins in a human melanoma
cell line (Hendrix et al., 1992) and in some leu.kaemic cells
which have lost vimentin expression when they are commit-
ted to differentiate by different treatments (Paulin Levasseur
et al., 1989; Jarvinen, 1990; Taimi et al., 1990; Tsuru et al.,
1990; Aller et al., 1992). The increase in vimentin expression
is sometimes accompanied by a decrease in keratin expression
(Sommers et al., 1992).
The DNA sequences regulating the expression of vimentin
have been cloned (Farrell et al., 1990; Hennekes et al., 1990;
Stover and Zehner, 1992; van de Klundert et al., 1992;
Salvetti et al., 1993; Lilienbaum and Paulin, 1993) and cer-
tain proteins keep the gene silent when bound to DNA
(Farrell et al., 1990; van de Klundert et al., 1992; Salvetti et
al., 1993), while others such as the NFKcB protein, activate its
expression (Lilienbaum and Paulin, 1993). The simultaneous
presence of both kinds of protein seems to result in inactiva-
tion of transcription (Salvetti et al., 1993).
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In a human breast cancer cell line made resistant to doxo-
rubicin there was an increase in the expression of vimentin
not detected in the wild-type cell line (Sommers et al.,
1992).
Considering the potential link between the acquisition of in
vitro resistance to doxorubicin and the expression of vimen-
tin, we tested two clones obtained from the human colocar-
cinoma cell line LoVo, with spontaneously different sensi-
tivity to doxorubicin (Dolfini et al., 1992, 1993; Monti et al.,
1993).
This system offers a good model for studying whether
vimentin expression is linked to the presence of P-glyco-
protein or can also be detected in cells expressing a low level
of P-glycoprotein-independent resistance to doxorubicin.
We evaluated the presence of vimentin at DNA, RNA and
protein level in the two clones, one of which (clone 7)
presents low-level resistance to doxorubicin, the drug being
three times less active than in clone 5 and in LoVo WT
(Dolfini et al., 1992, 1993; Monti et al., 1993). For com-
parison we used a LoVo subline pharmacologically made
resistant to doxorubicin (LoVo/DX), which expresses high
levels of the mdr-l mRNA encoding for the P-glycoprotein,
and presents a high level of resistance to doxorubicin (Grandi
et al., 1986).
Materias and metbods
Cell culture
The human colocarcinoma cell line LoVo was grown in vitro
in F12 medium supplemented with 10% fetal calf serum
(Mascra Brunelli, Milan, Italy) and maintained at 37C in a
5% carbon dioxide incubator. The two clones 5 and 7,
isolated from wild-type LoVo (LoVo WT), have been
recently described (Dolfini et al., 1992, 1993; Monti et al.,
1993) and were maintained in the same culture conditions.
LoVo/DX cells were isolated after repeated treatment of
LoVo WT cells with doxorubicin (Grandi et al., 1986).VImo.r_ uuinmhS '.Ik.
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DNA analysis
Total genomic DNA was isolated from monolayer cultures of
LoVo WT, LoVo clones 5 and 7 and LoVo/DX as described
previously (Southern, 1975), and digested to completion with
the restriction endonuclease BamHI. Ten micrograms of
DNA was separated on 0.8% agarose gel and transferred to
a nylon membrane (Genescreen Phls, Dupont). Filters were
baked for 2 h at 80C.
RNA anauysis
Total RNA was extracted with the guanidine isothiocyanate/
caesium chloride gradient method (Chirgwin et al., 1979) and
size fractionated through 1% agarose gel containig 6.5%
formakdehyde. The gel was then transferred to nylon mem-
brane (Genescreen Plus, Dupont) and baked for 2 h at
80-C.
Hybridisation
Both RNA and DNA filters were prehybridised for 3-6 h in
50% formamide, 10% dextran sulphate, 1% SDS (sodium
dodecyl sulphate), 1 M sodium chloride at 42-C. The filters
were hybridised in the same buffer containing 100 gml-'
denatured salmon sperm DNA and 5 x 1O c.p.m. ml-' 3P-
labelled probe.
The probes were labelled with the Megaprime kit (Amer-
sham) using the 1.2 kb BamHI fragment of human vimentin
(Ferrari et al., 1986) subcloned into the Blhscript SK, the
1.3 kb EcoRI-Sall fragment of the human mdr-I gene (Gros
et al., 1986) and the 1.3 kb PstI fragment of the murine
£-actin gene.
DNA transfection
Cells from clone 5 were transfected with the calcium phos-
phate procedure. Human vimentin c-DNA under the control
of cytomegalovirus (CMV) promoter (Sommers et al., 1992)
was transfected together with a neomycin expression plasmid
(pSV2Neo) to allow selection ofpositive colonies in geneticin
(500pgml-'). Doxorubicin sensitivity was in these
clones by treating the cells for 24 h with different drug con-
centrations and counting the number of cells after 72 h by
ining with (3[4,5-dimethylthiazol-2-yl2,5-diphenyltetrazo-
lium bromide) (MTr).
Immunofluorescence
Cells were plated on glass coverslips and grown for 24 h or
to confluency. They were washed once with phosphate-
buffered saline (PBS) containing 1 mM Ca2+ and 1 mM Mg2+
and fixed with 3% paraformaldehyde in PBS containing 2%
sucrose (15 min, room temperature). During three washes at
room temperature, residual paraformaklehyde cross-linkdng
activity was quenched by adding a drop of 1 M glycine,
pH 8.5, to the second and third PBS washes and leaving it 5
and IOmin respectively.
The samples were permeabilised with 0.5% Triton X-100
(Bio-Rad, CA, USA) in Hepes buffer (Hepes 20mM, sucrose
300mM, sodium chloride 50mM, magnesum chloride 3 mM),
4 min at 4'C, then washed twice with PBS and twice with
PBS-0.1% BSA (bovine serum albumin). For vinculin label-
hng at the cell-cell junction, cells were fixed for 5mm in
ice-cold methanol (-20 C) and then for lO s in ice-cold
acetone (-20 C).
Anti-vimentin mouse IgG, diluted 1:25 in DPBS (Dul-
becco's modified PBS)-1% BSA, was then added and
incubated for 30min at 3TC. Coverslips were rinsed once
with PBS and twice with PBS-0.1% BSA.
To double stain vimentin and F-actin filaments, rhoda-
mine-conjugated rabbit anti-mouse secondary antibodies
(diluted 1:40) and fluorescein-tagged phalloidin (2pgnml'1;
Sigma, St Louis, MO, USA), respectively, were mixed in
DPBS-1I% BSA, added to the coverslips and incubated for
30min at 3rC.
After extensive rinsing with PBS, coverslips were mounted
in Mowiol 4-88 (Hoechst, Frankfurt/Main, Germany) and
observed in a Zeiss Axiophot photomicroscope equipped for
epifluorescence (Carl Zeiss, Oberkochen, Germany). Fluores-
cent images were recorded on Kodak TMAX 400 films.
Immuocytochemistry
Cells were trypsinised and washed twice with PBS. Cytospin
preparations were made in a Shandon cytocentrifuge (500
r.p.m. for 10min). The cytospin preparations were air dried,
fixed in aceton at -20-C for 10min and stored at -20C
until stained. For immunocytochemical staining, cytospin
slides were incubated for 10min in 100ml of Tris buffer
pH 7.6 containing 1 ml of hydrogen peroxide solution (36%)
and 100mg of sodium azide to quench endogenous peroxi-
dase, then rinsed in Tris pH 7.6 and treated with 1.5% horse
serum for 20min. Primary antibody was applied for 30 min
at room temperature. Slides were then rinsed three times for
3min in 0.01% Triton X-100 in Tris.
Biotinylated secondary antiserum was then applied for
30min After rinses, the avidin-biotin-peroxidase complex
was allowed to react for 30min. Sections were incubated
with diaminobenzidine-hydrogen peroxide for 1 min, washed
in tap water, counterstained with Mayer's haematoxylin,
dehydrated and mounted. A negative control was made for
each sample by omitting the primary antibody.
Positively and negatively stained cells were counted in five
high-power (x 400) fields randomly selected in each cytospin
preparation. The boundaries of the field were marked out by
a grid in the eyepiece. Two cytospin preparations were
examined ifor each cell line. The results were expressed as the
mean percentage of positive cells ± s.d.
Antibodies
Mouse anti-vimentin IgG and rabbit anti-keratins serum
were obtained from Dako PAP Kit Systems (Dako, Carpin-
teria, CA, USA). Monoclonal anti-vinculin (ascitic fluid) was
from Sigma and was used at 1:150 dilution. Rhodamine-
conjugated rabbit anti-mouse secondary antibodies were
from Dakopatts (Glostrup, Denmark).
Res
LoVo clones 5 and 7 were selected from among many
different clones obtained from LoVo WT, on the basis of the
doxorubicin IC,1 (concentration inhibiting the growth ofcells
in vitro by 50%), which was respectively 16.8 and 48.9ng
ml-', compared with 16.1 ngml' for LoVo WT (Dolfini et
al., 1993). Thus, clone 7 has an intrinsically low level of
resiance to doxorubicin, being three times more resistant
than the parental cell line. For comparison, the ICEo of
LoVo/DX for doxorubicin is about 50 times that of LoVo
wr.
Clones 5 and 7 were analysed for the prsence of the
mRNA for the md--l gene. Figure 1 shows a gel hybridised
with the mdr-1 probe and reprobed with the actin gene to
check for correct loading. LoVo Wr did not express appre-
ciable levels of mdr-I mRNA which, however, was overex-
pressed in the LoVo/DX cells. mdr-l in clones 5 and 7 was
imilar to LoVo WT. The lack of mdr-l overexpression in
clone 7 confirmed previous reports of similar lels of doxo-
rubicin uptake and efflux in clones 5 and 7 and LoVo Wr
(Monti et a., 1993). In LoVo/DX, which overexpresses the
mdr-I mRNA, the efflux was much faster (Monti et al.,
1993).
When we analysed the different cell lines for the expression
of vimentn (Figure 2), we found that LoVo WT, as expec-
ted, did not express vimentin, while LoVo/DX overexpressed
it. The two clones behaved differently: clone 5, which has the
same doxorubicin ICs, as LoVo WT, did not express the gene
at mRNA level (like LoVo WT) but the more resistant clone
7 expressed it at high levels.fm_ . in in _ -"Ic _ iduibw Ies
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These studies were conducted at three different cell den-
sities to avoid any problem owing to density-related differ-
ences in expression. Lanes A show cells employed 24 h after
seeding, lanes C are the confluent monolayers and lanes B
are 50% confluency for all the lines used. Also shown is the
expression of vimentin mRNA in fibroblasts and keratino-
cytes maintained in culture (last two lns). Actin mRNA
was present in all the samples at all times after seeding.
We performed Southern blotting analysis to investigate
whether the overexpression of vimentin mRNA was due to
an amplification of the gene at DNA level (Figure 3). All
four cell lines contained only one copy of the vimentin gene
which was not amplified in clones highly expressng
mRNA.
The four cell lines were finally characteriWd for protein
expression, in order to find any correlation between mRNA
and protein level. We used immunofluorescen microscopy
to investigate the presence and organisation ofvimentin. The
same specimen was staied for vimenti and actn by double
labelling. The vimentin filaments were det with a MAb
(monoclonal antibody) to vimentin, revealed by a second
antibody, rhodamine-conjugated rabbit anti-mouse IgG, and
actin filaments were det by fluorescin-conjugated phal-
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loidin fluorescence. Figure 4 shows cells at low density
stained for vimentin (a-d) and actin (e-h) filaments. Vimen-
tin staining was mostly negative for the parental cell line and
for clone 5, only a few cells giving a positive signal (Figure
4a and b, see arrows). However, clone 7 and LoVo/DX
resistant cell lines showed strong vimentin positivity (Figure
4c and d). Positivity for actin filaments was observed running
along the cell borders in all four cell lines (Figure 4 e-h).
Actin filaments crossing the cell cytoplasm were found when
speamens were observed at a different focus (see Figure
4g).
Vimentin staining gave similar results on cells at conflu-
ency (Figure 5). Only a few cells were positive for vimentin in
LoVo WT confluent monolayers, and there are none in the
field shown (Figure 5a). There were more positive cells for
vimentin in confluent monolayers of clone 5 (Figure 5b, see
arrows). Cells in confluent monolayers of clone 7 and LoVo/
DX were mostly positive (see below for quantitative
analysis).
T'he actin filament organisation at the cell borders obser-
ved at low density was more marked with cells grown to
confluency (Figures 5 e-g). This pattern, however, was almost
mpletely lost in the LoVo/DX cell line (Figure 5h),
suggestng that the actin filanent organisation of these cells
may be modified at the cell-cell contacts. To better charac-
tense the cell-cell junctions in LoVo/DX cells, we tested
vinculin, a second component of the zonula adherens, by
immunofluorescence in confluent monolayers. In LoVo WT
cells anti-vinculin antibody showed discrete ines of staining
at cell-cell borders, indicating junctions linking adjacent
cells. In contrast, in LoVo/DX cells the same antibody
showed only background cytoplasmic staining also observed
with non-immune IgG (data not shown), as observed above
for actin saining.
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Fugwe 1 Northern blot analysis of m-I expression LoVo
WT (lane 1), LoVo cone 5 (lane 2), LoVo e 7 (lane 3) and
LoVo/DX (lane 4). The filer was first hybridi to the nmh-1
probe and subsequently rehybridsed to the acti probe to nor-
mase the amount of RNA loaded in each line.
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Fugwe 2 Vimentin exprssonmin LoVo WT, LoVo clone 5,
LoVo clone 7 and LoVo/DX. Cells we evaluated at different
densities (A) 24 h after seeding, (B) 50% confluency, (C)
confluent monolayers. HF and NCTC stand for human fibro-
blasts and keratnocytes mamtaied m culture. Tbe filter was first
hybridied to the vimentin probe and subsequetly to the actn
probe to normahse the amount of RNA oaded m each lane. The
figure also contains the ethidium bromide-stained agarose gel
showing the position of the two ribosomal RNA.
Fugwe 3 Southern blot analysis: 10 ag of BrnHi-digested DNA
was separated on agarose gd, transferred to a nylon filter and
hybridised with vimentin probe. Lane 1, LoVo WT; lane 2, clone
5; lane 3, clone 7; and lane, 4 LoVo/DX. The figure also contains
the ethidium bromid-stained agarose gel showing the amount of
DNA klded for each sample.
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We used an immunohistochemistry technique to quantify
the number of vimentin-positive cells in these four cell lines
(Table I). As already observed by immunofluorescence in
LoVo WT and LoVo clone 5. the cells were mainly negative
for vimentin (3.6% and 8.6% of positive cells respectively for
the two lines). In LoVo clone 7 and LoVo/DX the propor-
tions of positive cells were much higher (71% and 98%
respectively). Thus, fluorescence and immunohistochemistry
data for vimentin intermediate filaments are in agreement
with the level of mRNA found in these cells. The four cell
lines expressed keratins at similar levels (data not shown).
After transfection of cells from clone 5 with vimentin
cDNA, we selected seven clones which express vimentin
mRNA differently (Table II). The clones expressing vimentin
at levels similar to those found in clone 7 did not have
significantly different sensitivity to DX, each clone being as
sensitive as, if not more than, the parental clone 5 from
which they derive, independently on vimentin expression. The
mRNA data were confirmed by immunofluorescence labelling
of vimentin and clones expressing mRNA express protein as
well (data not shown).
Figure 4 Vimentin and actin detection on LoVo (a and e). clone 5 (b and f), clone 7- (c and g) and LoVo 'DX cells (d and h) (at
low density) by double-immunofluorescence labelling. Cells were seeded on glass coverslips and cultured for 24 h. They were
washed once. fixed and permeabilised (see Materials and methods section). Vimentin distribution (a-d) was detected by rhodamine
fluorescence and actin distribution (e-h) by fluorescein fluorescence. Vimentin appears strongly stained on the majority of clone 7
and LoVo DX cells (c and d). whereas very few cells were positively stained in the LoVo parental and clone 5 lines (a and b, see
arrows). Actin filaments were detected either at cell-cell boundaries, where they belong to the zonula adherens that contributes to
cell-cell adhesion, or organised in stress fibres crossing the cells and terminating in focal contacts. At these sites they connect the
cell with the substratum. The two different actin distributions were distinguished by focusing on different planes of the specimens.
Bar = 20Lm-The mechanisms of drug resistance of cancer cells in vivo are
still not clear. For anthracycine antibiotics, particularly
doxorubicin, the major factor in vitro is the P-glycoprotein
encoded by the mdr gene family (Endicott and Ling, 1989;
van der Bliek and Borst, 1989), which acts like a pump,
removing the drug from the intracellular compartment. Other
mechanisms involve the modification of topoisomerase II
enzymatic activity, which is one of the targets of doxo-
rubicin's action (Schneider et al., 1990; Zunino and Capran-
Vimeuli exsionm oobcnreitn km lte
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ico, 1990; Cole et al., 1991). Agents that block P-glyco-
protein, such as calcium channel blockers, almost completely
reverse the doxorubicin resistance of many resistant cancer
cells (Ford and Hait, 1990). However even when the intracel-
lular drug levels are brought back to the same as in parental
cells, a certain degree of resistance persists (Broggini et al.,
1988; Ford and Hait, 1990), suggesting that in vitro other
mechanisms besides mdr-1 gene overexpression are respon-
sible, particularly for low levels of drug resistance.
We isolated clones from the parental line LoVo with
different degrees of susceptibility to doxorubicin. Two clones
Fiwe 5 Vimentin and actin detection on LoVo (a and e), clone 5 (b and f), clone 7 (c and g) and LoVo DX (d and h) cells (at
high density) by double-immunofluorescence labelling. Cells were seeded on glass coverslips and grown to confluency. Specimens
were prepared as described in the legend to Figure 4. Vimentin distribution (a-d) was detected by rhodamine fluorescence and
actin distribution (e-b) by fluorescein fluorescence. As for low-density cells, the vimentin staining was homogeneously distributed
on clone 7 and LoVo DX cells (c and d) but only very few LoVo parental and clone 5 cells were positively stained. The majority of
the microscopic fields for LoVo WT had no positive vimentin cells (a) compared with clone 5 (b, see arrows) in which the positivity
was slighter higher. At high cell density, when the cell-cell contacts were well established, actin filaments were strongly stained
along the cell borders (e-g). The thick line running along the cells appeared much thinner on LoVo DX cells, even where cell-cell
contacts were maintained (h). Bar = 20pm.Vknuntin ezrsianh on ci-resHICsti ci hiskm
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Table I Vimentin-positive cells in cytospin preparations
Cell line Positive cells (%±s.d.)
LoVo WT 3.6±1.4
LoVo Clone 5 8.6±2.4
LoVo Clone 7 70.7±6.5
LoVojDX 98.0±1.7
Results arethemean±s.d. offivedifferent readingsineach preparation.
Samples were run in duplicate for each cell line.
Table H Sensitivity to doxorubicin in clones transfected with the
human vimentin cDNA
Cell clones mRNA' vimentin!actin IC50 DXA
Clone 5 1.0 1.0
Clone 7 6.2 3.2
CloneSVl 3.1 1.0
Clone 5 V2 0.6 0.8
Clone 5 V3 5.3 0.4
Clone 5 V4 1.7 0.7
Clone 5 V5 2.4 0.8
Clone 5 V6 5.3 0.8
Clone 5 V7 2.6 0.7
'Ratioofvimentin toactinmRNAdeterminedbydensitometricanalysis
ofthe autoradiograms. The LoVo clone 5 value wasarbitrarily set at 1.
bRatio ofdoxorubicin IC50 found in the differentclones to clone5. The
values were obtained from two experiments each consisting of six
replicates per dose per clone. Clone 5 VI -V7: clones obtained by
transfecting clone 5 cells with the human vimentin cDNA.
were selected, clone 5 showing a doxorubicin IC53 similar to
the parental line and clone 7 a three times higher IC50
(Dolfini et al., 1992, 1993). These clones express P-glyco-
protein at similar levels, in agreement with a previous obser-
vation showing that they accumulate the drug at similar
intracellular levels (Monti et al., 1993). They are therefore a
good experimental model for seeking other mechanisms in-
volved in doxorubicin resistance.
We compared our results with the LoVo/DX cell line made
resistant pharmacologically which expresses high levels of
amplification of the mdr-l gene. We considered the expres-
sion of the intermediate filament vimentin because it was
atypically expressed in a breast carcinoma cell line made
resistant to doxorubicin (Sommers et at., 1992).
We confirmed the lack of expression of vimentin in the
epithelial cell line LoVo and its high expression in LoVo,/DX
cells, measured by Northern analysis. Clone 5 did not express
vimentin mRNA but the resistant clone 7 did. The levels of
expression in clone 7 and LoVo/DX were similar and seemed
to be unrelated to expression of P-glycoprotein.
These mRNA data were confirmed at protein level by
either immunofluorescence or immunohistochemistry. Both
LoVo WT and clone 5 were almost negative for vimentin
antibody with very few positive cells. Clone 7 and LoVo/DX
presented high expression, the majority of the cells being
positive for vimentin antibody. The pattern of vimentin
filament expression in confluent monolayers of clone 7 looks
quite different from that at lower cell density (compare
Figure 4c with Figure Sc). This is very likely due to more
limited cell spreading in confluent monolayers or to a specific
organisation of vimentin in these cells at confluency. This
point needs further clarification.
Many cells from confluent LoVo,/DX monolayers were
recovered in the supernatant. This can be explained by the
altered actin and vinculin organisation at the cell borders,
supporting previous findings of altered distribution of cell
junction molecules in cells expressing mdr (Sommers et al.,
1992).
The expression ofvimentin has been reported to be accom-
panied by a loss of keratin expression (Paine et al., 1992;
Sommers et al., 1992). These proteins are expressed in LoVo/
DX and clone 7 (data not shown) and do not appear to be
down-regulated. The vimentin expression is not due to an
amplification of the gene at the DNA, as shown by Southern
blotting analysis, but it might be due to either a stabilisation
of the mRNA or an increase in the transcription rate. We
have preliminary data (unpublished) suggesting that at least
the NFxB binding to the human vimentin promoter is un-
changed in the four clones tested.
Our results show for the first time that, independently of
the presence of the mdr glycoprotein, cells showing a low
level of resistance to doxorubicin do express high levels of
vimentin, whereas the parental cell line contains only very
small amounts. The data on clones transfected with the
human vimentin cDNA, however, indicate that vimentin ex-
pression per se does not induce a resistant phenotype (at least
in the clones tested so far) in these cells but can be con-
sidered as a marker of resistance and more generally, as
already shown for other cell lines (Sommers et al., 1992), as a
marker of malignancy for certain types of cancer cells nor-
mally not expressing vimentin.
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